Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1950 1
1952 1
1953 1
1954 2
1955 2
1956 2
1957 1
1960 1
1961 4
1962 4
1963 2
1966 2
1967 1
1968 3
1969 1
1970 3
1971 2
1972 4
1973 2
1975 1
1976 1
1977 3
1978 2
1979 4
1980 6
1981 7
1982 4
1983 4
1984 10
1985 12
1986 9
1987 14
1988 13
1989 27
1990 12
1991 13
1992 23
1993 25
1994 30
1995 29
1996 21
1997 18
1998 29
1999 33
2000 37
2001 33
2002 42
2003 42
2004 35
2005 57
2006 46
2007 48
2008 49
2009 65
2010 56
2011 66
2012 65
2013 68
2014 58
2015 78
2016 79
2017 73
2018 78
2019 63
2020 98
2021 111
2022 102
2023 79
2024 66

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

1,803 results

Results by year

Filters applied: . Clear all
Page 1
Effect of Continued Weekly Subcutaneous Semaglutide vs Placebo on Weight Loss Maintenance in Adults With Overweight or Obesity: The STEP 4 Randomized Clinical Trial.
Rubino D, Abrahamsson N, Davies M, Hesse D, Greenway FL, Jensen C, Lingvay I, Mosenzon O, Rosenstock J, Rubio MA, Rudofsky G, Tadayon S, Wadden TA, Dicker D; STEP 4 Investigators. Rubino D, et al. Among authors: rubio ma. JAMA. 2021 Apr 13;325(14):1414-1425. doi: 10.1001/jama.2021.3224. JAMA. 2021. PMID: 33755728 Free PMC article. Clinical Trial.
Lurbinectedin as second-line treatment for patients with small-cell lung cancer: a single-arm, open-label, phase 2 basket trial.
Trigo J, Subbiah V, Besse B, Moreno V, López R, Sala MA, Peters S, Ponce S, Fernández C, Alfaro V, Gómez J, Kahatt C, Zeaiter A, Zaman K, Boni V, Arrondeau J, Martínez M, Delord JP, Awada A, Kristeleit R, Olmedo ME, Wannesson L, Valdivia J, Rubio MJ, Anton A, Sarantopoulos J, Chawla SP, Mosquera-Martinez J, D'Arcangelo M, Santoro A, Villalobos VM, Sands J, Paz-Ares L. Trigo J, et al. Among authors: rubio mj. Lancet Oncol. 2020 May;21(5):645-654. doi: 10.1016/S1470-2045(20)30068-1. Epub 2020 Mar 27. Lancet Oncol. 2020. PMID: 32224306 Clinical Trial.
Central Ceramide Signaling Mediates Obesity-Induced Precocious Puberty.
Heras V, Castellano JM, Fernandois D, Velasco I, Rodríguez-Vazquez E, Roa J, Vazquez MJ, Ruiz-Pino F, Rubio M, Pineda R, Torres E, Avendaño MS, Paredes A, Pinilla L, Belsham D, Diéguez C, Gaytán F, Casals N, López M, Tena-Sempere M. Heras V, et al. Among authors: rubio m. Cell Metab. 2020 Dec 1;32(6):951-966.e8. doi: 10.1016/j.cmet.2020.10.001. Epub 2020 Oct 19. Cell Metab. 2020. PMID: 33080217 Free article.
Atezolizumab plus bevacizumab and chemotherapy for metastatic, persistent, or recurrent cervical cancer (BEATcc): a randomised, open-label, phase 3 trial.
Oaknin A, Gladieff L, Martínez-García J, Villacampa G, Takekuma M, De Giorgi U, Lindemann K, Woelber L, Colombo N, Duska L, Leary A, Godoy-Ortiz A, Nishio S, Angelergues A, Rubio MJ, Fariñas-Madrid L, Yamaguchi S, Lorusso D, Ray-Coquard I, Manso L, Joly F, Alarcón J, Follana P, Romero I, Lebreton C, Pérez-Fidalgo JA, Yunokawa M, Dahlstrand H, D'Hondt V, Randall LM; ENGOT-Cx10–GEICO 68-C–JGOG1084–GOG-3030 Investigators. Oaknin A, et al. Among authors: rubio mj. Lancet. 2024 Jan 6;403(10421):31-43. doi: 10.1016/S0140-6736(23)02405-4. Epub 2023 Dec 1. Lancet. 2024. PMID: 38048793 Clinical Trial.
Detection, treatment and prevention programs for gestational diabetes mellitus: The St Carlos experience.
Assaf-Balut C, García de la Torre N, Calle-Pascual AL; St. Carlos Study Group; Calle-Pascual AL, Torre NG, Durán A, Jiménez I, Rubio MÁ, Herraíz MÁ, Izquierdo N, Pérez N, Garcia AS, Dominguez GC, Torrejón MJ, Cuadrado MÁ, Assaf-Balut C, Del Valle L, Bordiú E, Valerio J, Barabash A, Orta MS, Parayuelo MVS, Muñoz LF, Calzada F; All members of St Carlos Study Group have read and agreed with the content of the last version of manuscript. Each member named has participated actively and sufficiently in the case reported and fulfilled all conditions as authors. Assaf-Balut C, et al. Among authors: rubio ma. Endocrinol Diabetes Nutr (Engl Ed). 2020 May;67(5):342-350. doi: 10.1016/j.endinu.2019.06.007. Epub 2019 Sep 11. Endocrinol Diabetes Nutr (Engl Ed). 2020. PMID: 31519528 Review. English, Spanish.
Allogeneic transplantation in advanced cutaneous T-cell lymphomas (CUTALLO): a propensity score matched controlled prospective study.
de Masson A, Beylot-Barry M, Ram-Wolff C, Mear JB, Dalle S, d'Incan M, Ingen-Housz-Oro S, Orvain C, Abraham J, Dereure O, Charbonnier A, Cornillon J, Longvert C, Barete S, Boulinguez S, Wierzbicka-Hainaut E, Aubin F, Rubio MT, Bernard M, Schmidt-Tanguy A, Houot R, Pham-Ledard A, Michonneau D, Brice P, Labussière-Wallet H, Bouaziz JD, Grange F, Moins-Teisserenc H, Jondeau K, Michel L, Mourah S, Battistella M, Daguindau E, Loschi M, Picard A, Franck N, Maillard N, Huynh A, Nguyen S, Marçais A, Chaby G, Ceballos P, Le Corre Y, Maury S, Bay JO, Adamski H, Bachy E, Forcade E, Socié G, Bagot M, Chevret S, Peffault de Latour R; CUTALLO Investigators; Groupe Français d'Etude des Lymphomes Cutanés; Société Française de Greffe de Moëlle et Thérapie Cellulaire. de Masson A, et al. Among authors: rubio mt. Lancet. 2023 Jun 10;401(10392):1941-1950. doi: 10.1016/S0140-6736(23)00329-X. Epub 2023 Apr 24. Lancet. 2023. PMID: 37105210
Predictive factors of early progression after CAR T-cell therapy in relapsed/refractory diffuse large B-cell lymphoma.
Vercellino L, Di Blasi R, Kanoun S, Tessoulin B, Rossi C, D'Aveni-Piney M, Obéric L, Bodet-Milin C, Bories P, Olivier P, Lafon I, Berriolo-Riedinger A, Galli E, Bernard S, Rubio MT, Bossard C, Meignin V, Merlet P, Feugier P, Le Gouill S, Ysebaert L, Casasnovas O, Meignan M, Chevret S, Thieblemont C. Vercellino L, et al. Among authors: rubio mt. Blood Adv. 2020 Nov 24;4(22):5607-5615. doi: 10.1182/bloodadvances.2020003001. Blood Adv. 2020. PMID: 33180899 Free PMC article.
[Awareness on the law of bioethics].
Bay JO, Dalle JH, Dulery R, Magro L, Nguyen-Quoc S, Robin M, Rubio MT, Huynh A. Bay JO, et al. Among authors: rubio mt. Bull Cancer. 2020 May;107(5):541-542. doi: 10.1016/j.bulcan.2020.04.005. Epub 2020 Apr 30. Bull Cancer. 2020. PMID: 32386707 French. No abstract available.
Ophthalmological Manifestations of Hereditary Myopathies.
Saint-Gerons M, Rubio MA, Aznar G, Matheu A. Saint-Gerons M, et al. Among authors: rubio ma. J Binocul Vis Ocul Motil. 2022 Jan-Mar;72(1):4-17. Epub 2022 Jan 20. J Binocul Vis Ocul Motil. 2022. PMID: 35049410 Review.
Biologie, concepts et principes des CAR-T cells.
Rubio MT, Galaine J, Borg C, Daguindau É. Rubio MT, et al. Bull Cancer. 2018 Dec;105 Suppl 2:S135-S146. doi: 10.1016/S0007-4551(19)30044-X. Bull Cancer. 2018. PMID: 30686352 French.
1,803 results